Clinical Trial Update: BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating BI-836845 in combination with Enzalutamide for castration-resistant prostate cancer has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• BI 836845
• Enzalutamide (enzalutamide)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Prostatic Neoplasms, Castration-Resistant | Phase 1 | Status: COMPLETED | Results posted: 2025-07-15